Skip to main content
SpringerLink
Log in

New Atypical Antipsychotics

Experience and Utility in the Elderly

  • Review Article
  • Drug Therapy
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

The atypical antipsychotics are a new class of agents with great promise for use in the elderly because of their reduced propensity to cause acute extrapyramidal adverse effects. Treatment of older patients with these agents, however, needs to take into consideration age-related changes in pharmacokinetics and the risks of drug-drug interactions. Additionally, current evidence of their efficacy in late-life psychoses is derived largely from case series and from the extrapolation of results obtained in studies of younger patients with schizophrenia. Controlled clinical studies of atypical antipsychotics in elderly patients are urgently needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Beers M, Avorn J, Soumerai SB, et al. Psychoactive medication use in intermediate-care facility residents. JAMA 1988; 260: 3016–20

    Article  PubMed  CAS  Google Scholar 

  2. Ray WA, Federspiel CF, Schaffner W. A study of antipsychotic drug use in nursing homes: epidemiologic evidence suggesting misuse. Am J Public Health 1980; 70: 485–91

    Article  PubMed  CAS  Google Scholar 

  3. Pollock BG, Mulsant BH. Antipsychotics in older patients: a safety perspective. Drugs Aging 1995; 6: 312–23

    Article  PubMed  CAS  Google Scholar 

  4. Jeste DV, Eastham JH, Lacro JP, et al. Management of late-life psychosis. J Clin Psychiatry 1996; 57: 39–45

    PubMed  Google Scholar 

  5. Katzman R. Education and the prevalence of dementia and Alzheimer’s disease. Neurology 1993; 43: 13–20

    Article  PubMed  CAS  Google Scholar 

  6. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993; 21: 457–78

    PubMed  CAS  Google Scholar 

  7. Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer’s disease: a natural history study. J Am Geriatr Soc 1996; 44: 1078–81

    PubMed  CAS  Google Scholar 

  8. Drevets WC, Rubin EH. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biol Psychiatry 1989; 25: 39–48

    Article  PubMed  CAS  Google Scholar 

  9. Zubenko GS, Rosen J, Sweet RA, et al. Impact of psychiatric hospitalization on behavioral complications of Alzheimer’s disease. Am J Psychiatry 1992; 149: 1484–91

    PubMed  CAS  Google Scholar 

  10. Swearer JM, Drachman DA, O’Donnell BF, et al. Troublesome and disruptive behaviors in dementia: relationships to diagnosis and disease severity. J Am Geriatr Soc 1988; 36: 784–90

    PubMed  CAS  Google Scholar 

  11. Magni E, Binetti G, Bianchetti A, et al. Risk of mortality and institutionalization in demented patients with delusions. J Geriatr Psychiatry Neurol 1996; 9: 123–6

    PubMed  CAS  Google Scholar 

  12. Steele C, Rovner BW, Chase GA, et al. Psychiatric symptoms and nursing home placement of patients with Alzheimer’s disease. Am J Psychiatry 1990; 147: 1049–51

    PubMed  CAS  Google Scholar 

  13. Devanand DP, Levy SR. Neuroleptic treatment of agitation and psychosis in dementia. J Geriatr Psychiatry Neurol 1995; 8Suppl. 1: S18–27

    Article  PubMed  Google Scholar 

  14. Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38: 553–63

    PubMed  CAS  Google Scholar 

  15. Schneider LS, Sobin PB. Non-neuroleptic medications in the management of agitation in Alzheimer’s disease and other dementia: a selective review. Int J Geriatr Psychiatry 1991; 6: 691–708

    Article  Google Scholar 

  16. Abse DW, Dahlstrom WG, Hill C. The value of chemotherapy in senile mental disturbances: controlled comparison of chlorpromazine, reserpine-pipradrol, and opium. JAMA 1960; 174: 2036–42

    Article  PubMed  CAS  Google Scholar 

  17. Hamilton LD, Bennett JL. Acetophenazine for hyperactive geriatric patients. Geriatrics 1962; 17: 596–601

    PubMed  CAS  Google Scholar 

  18. Hamilton LD, Bennett JL. The use of trifluoperazine in geriatric patients with chronic brain syndrome. J Am Geriatr Soc 1962; 10: 140–7

    PubMed  CAS  Google Scholar 

  19. Sugerman AA, Williams BH, Adlerstein AM. Haloperidol in the psychiatric disorders of old age. Am J Psychiatry 1964; 120: 1190–2

    PubMed  CAS  Google Scholar 

  20. Barnes R, Veith R, Okimoto J, et al. Efficacy of antipsychotic medications in behaviorally disturbed dementia patients. Am J Psychiatry 1982; 139: 1170–4

    PubMed  CAS  Google Scholar 

  21. Petrie WM, Ban TA, Berney S, et al. Loxapine in psychogeriatrics: a placebo- and standard-controlled clinical investigation. J Clin Psychopharmacol 1982; 2: 122–6

    Article  PubMed  CAS  Google Scholar 

  22. Finkel SI, Lyons JS, Anderson RL, et al. A randomized, placebocontrolled trial of thiothixene in agitated, demented nursing home patients. Int J Geriatr Psychiatry 1995; 10: 129–36

    Article  Google Scholar 

  23. Rada RT, Kellner R. Thiothixene in the treatment of geriatric patients with chronic organic brain syndrome. J Am Geriatr Soc 1976; 24: 105–7

    PubMed  CAS  Google Scholar 

  24. Davis JM. Antipsychotic drugs. In: Kaplan HI, Sadock BJ, editors. Comprehensive textbook of psychiatry. 4th ed. Baltimore: Williams & Wilkins, 1985: 1481–513

    Google Scholar 

  25. Seeman P. Dopamine receptor sequences: therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 1992; 7: 261–84

    PubMed  CAS  Google Scholar 

  26. Victoroff J, Zarow C, Mack WJ, et al. Physical aggression is associated with preservation of substantia nigra pars compacta in Alzheimer disease. Arch Neurol 1996; 53: 428–34

    Article  PubMed  CAS  Google Scholar 

  27. Lopez OL, Kaufer D, Reiter CT, et al. Relationship between CSF neurotransmitter metabolites and aggressive behavior in Alzheimer’s disease. Eur J Neurol 1996; 3: 153–5

    Article  Google Scholar 

  28. Sweet RA, Pollock BG, Mulsant BH, et al. Association of plasma homovanillate with behavioral symptoms in patients diagnosed with dementia: a preliminary report. Biol Psychiatry 1997; 42: 1016–23

    Article  PubMed  CAS  Google Scholar 

  29. Sweet RA, Nimgaonkar VL, Kamboh MI, et al. Genetic variation, psychosis, and aggression in Alzheimer’s disease. Soc Neurosci Abst 1997; 23: 29

    Google Scholar 

  30. Sweet RA, Pollock BG, Mulsant BH, et al. D2 receptor pharmacodynamics correlate with psychosis in dementia of the Alzheimer’s type. Psychopharmacol Bull 1997; 33(3): 594

    Google Scholar 

  31. Palmer AM, DeKosky ST. Monoamine neurons in aging and Alzheimer’s disease. J Neural Transm 1993; 91: 135–59

    Article  CAS  Google Scholar 

  32. Sweet RA, Pollock BG. Neuroleptics in the elderly: guidelines for monitoring. Harvard Rev Psychiatry 1995; 2: 327–35

    Article  CAS  Google Scholar 

  33. Sweet RA, Mulsant BH, Pollock BG, et al. Neuroleptic-induced parkinsonism in elderly patients diagnosed with psychotic major depression and dementia of the Alzheimer type. Am J Geriatr Psychiatry 1996; 4: 311–9

    Google Scholar 

  34. Weiner MF, Risser RC, Cullum CM, et al. Alzheimer’s disease and its Lewy body variant: a clinical analysis of postmortem verified cases. Am J Psychiatry 1996; 153: 1269–73

    PubMed  CAS  Google Scholar 

  35. McKeith I, Fairbairn A, Perry R, et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992; 305: 673–8

    Article  PubMed  CAS  Google Scholar 

  36. Wilson JA, MacLennan WJ. Review: drug-induced parkinsonism in elderly patients. Age Ageing 1989; 18: 208–10

    Article  PubMed  CAS  Google Scholar 

  37. Pollock BG, Perel JM, Reynolds CF, et al. Pharmacodynamic issues relevant to geriatric psychopharmacology. J Geriatr Psychiatry Neurol 1990; 3: 221–8

    Article  PubMed  CAS  Google Scholar 

  38. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995; 52: 756–65

    Article  PubMed  CAS  Google Scholar 

  39. Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 1993; 54: 133–9

    PubMed  CAS  Google Scholar 

  40. Sweet RA, Mulsant BH, Gupta B, et al. Duration of neuroleptic treatment and prevalence of tardive dyskinesia in late life. Arch Gen Psychiatry 1995; 52: 478–86

    Article  PubMed  CAS  Google Scholar 

  41. Borison RL. Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J Clin Psychopharmacol 1995; 15(1 Suppl. 1): 24S–9S

    Article  PubMed  CAS  Google Scholar 

  42. Meltzer HY. Serotonin-dopamine interactions and atypical antipsychotic drugs. Psychiatr Ann 1993; 23: 193–200

    Google Scholar 

  43. Carter CS, Mulsant BH, Sweet RA, et al. Risperidone use in a teaching hospital during its first year after market approval: economic and clinical implications. Psychopharmacol Bull 1995; 31: 719–25

    PubMed  CAS  Google Scholar 

  44. Pollock BG. Recent developments in drug metabolism of relevance to psychiatrists. Harvard Rev Psychiatry 1995; 2: 204–13

    Article  Google Scholar 

  45. Pollock BG, Perel JM, Altieri LP, et al. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology. Psychopharmacol Bull 1992; 28: 163–8

    PubMed  CAS  Google Scholar 

  46. Armstrong M, Daly AK, Cholerton S, et al. Mutant debrisoquine hydroxylase genes in Parkinson’s disease. Lancet 1992; 339: 1017–8

    Article  PubMed  CAS  Google Scholar 

  47. Smith AD, Gough AC, Leigh PN, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson’s disease. Lancet 1992; 339: 1375–7

    Article  PubMed  CAS  Google Scholar 

  48. Ring BJ, Catlow J, Lindsay TJ, et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996; 276: 658–66

    PubMed  CAS  Google Scholar 

  49. Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38: 402–8

    Article  PubMed  CAS  Google Scholar 

  50. Pollock BG, Mulsant BH, Sweet RA, et al. An open pilot study of citalopram for behavioral disturbances of dementia: plasma levels and real-time observations. Am J Geriatr Psychiatry 1996; 5: 70–8

    Google Scholar 

  51. Grimm SW, Stams KR, Bui K. In vitro prediction of potential metabolic drug interactions for quetiapine [abstract]. Proceedings of the American Psychiatric Association (APA) 150th Annual Meeting; new research program and abstracts. San Diego (CA); 1997 May 17–22; 135

  52. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996; 57: 12–25

    PubMed  CAS  Google Scholar 

  53. Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly: therapeutic considerations (part I). Clin Pharmacokinet 1991; 21: 165–77

    Article  PubMed  CAS  Google Scholar 

  54. Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly: therapeutic considerations (part II). Clin Pharmacokinet 1991; 21: 262–73

    Article  PubMed  CAS  Google Scholar 

  55. Pollock BG. Gender differences in psychotropic drug metabolism. Psychopharmacol Bull 1997; 33: 235–41

    PubMed  CAS  Google Scholar 

  56. Butler MA, Lang NP, Young JF, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2: 116–27

    Article  PubMed  CAS  Google Scholar 

  57. Zeeh J, Fuchs L, Bergmann W, et al. Influence of age, frailty and liver function on the pharmacokinetics of brofaromine. Eur J Clin Pharmacol 1996; 49: 387–91

    Article  PubMed  CAS  Google Scholar 

  58. Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989; 25: 390–2

    PubMed  CAS  Google Scholar 

  59. Chengappa KNR, Baker RW, Kreinbrook SB, et al. Clozapine use in female geriatric patients with psychosis. J Geriatr Psychiatry Neurol 1995; 8: 12–5

    PubMed  CAS  Google Scholar 

  60. Oberholzer AF, Hendriksen C, Monsch AU, et al. Safety and effectiveness of low-dose clozapine in psychogeriatric patients: a preliminary study. Int Psychogeriatr 1992; 4: 187–95

    Article  PubMed  CAS  Google Scholar 

  61. Salzman C, Vaccaro B, Lieff J, et al. Clozapine in older patients with psychosis and behavioral disruption. Am J Geriatr Psychiatry 1995; 3: 26–33

    Google Scholar 

  62. Richards SS, Sweet RA, Ganguli R. Clozapine: acute and maintenance treatment in late-life psychoses. Am J Geriatr Psychiatry 1996; 4: 377–8

    Google Scholar 

  63. Lew MF, Waters CH. Clozapine treatment of parkinsonism with psychosis. J Am Geriatr Soc 1995; 41: 669–71

    Google Scholar 

  64. Factor SA, Brown D, Molho ES, et al. Clozapine: a 2-year open trial in Parkinson’s disease patients with psychosis. Neurology 1994; 44: 544–6

    Article  PubMed  CAS  Google Scholar 

  65. Wolters EC, Hurwitz TA, Mak E, et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 1990; 40: 832–4

    Article  PubMed  CAS  Google Scholar 

  66. Jansen ENH. Clozapine in the treatment of tremor in Parkinson’s disease. Acta Neurol Scand 1994; 89: 262–5

    Article  PubMed  CAS  Google Scholar 

  67. Wolk SI, Douglas CJ. Clozapine treatment of psychosis in Parkinson’s disease: a report of five consecutive cases. J Clin Psychiatry 1992; 53: 373–6

    PubMed  CAS  Google Scholar 

  68. Freidman JH, Lannon MC. Clozapine in the treatment of psychosis in Parkinson’s disease. Neurology 1989; 39: 1219–21

    Article  Google Scholar 

  69. Hildebrand J, Delecluse F. Effect of ritanserin, a selective serotonin-S2 antagonist, on parkinsonian rest tremor. Curr Ther Res 1987; 41: 298–300

    Google Scholar 

  70. Haring C, Fleischhacker WW, Schett P, et al. Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry 1990; 147: 1471–5

    PubMed  CAS  Google Scholar 

  71. Centorrino F, Baldessarini RJ, Flood JG, et al. Relation of leukocyte counts during clozapine treatment to serum concentrations of clozapine and metabolites. Am J Psychiatry 1995; 152: 610–2

    PubMed  CAS  Google Scholar 

  72. Richelson E. Preclinical pharmacology of antipsychotic drugs: relationship to efficacy and side effects. J Clin Psychiatry Monograph 1994; 12: 17–20

    Google Scholar 

  73. Zorn SH, Jones SB, Ward KM, et al. Clozapine is a potent and selective muscarinic M4 receptor agonist. Eur J Pharmacol 1994; 269: R1–2

    Article  PubMed  CAS  Google Scholar 

  74. Vasile JS, Steingard S. Clozapine and the development of salivary gland swelling: a case study. J Clin Psychiatry 1995; 56: 511–3

    PubMed  CAS  Google Scholar 

  75. Honigfeld G. The clozapine national registry system: forty years of risk management. J Clin Psychiatry Monograph 1996; 14: 29–32

    Google Scholar 

  76. Alvir JJ, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993; 329: 162–7

    Article  PubMed  CAS  Google Scholar 

  77. Madhusoodanan S, Brenner R, Araujo L, et al. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry 1995; 56: 514–8

    PubMed  CAS  Google Scholar 

  78. Jeanblanc W, Davis YB. Risperidone for treating dementia-associated aggression [letter]. Am J Psychiatry 1995; 152: 1239

    PubMed  CAS  Google Scholar 

  79. Aronson SM, Lingam V, Hasanat KA. Risperidone in geropsychiatry: review of early experience in two public hospitals [abstract]. Proceedings of the American Psychiatric Association (APA) 148th Annual Meeting: new research program and abstracts. Miami; 1995 May 20–25; 127

  80. Borison RL, Davidson M, Berman I. Risperidone treatment in elderly patients with schizophrenia or dementia. Proceedings of the American Psychiatric Association (APA) 46th Institute of Hospital and Community Psychiatry; 1994

  81. Goldberg RJ. Risperidone for dementia-related disturbed behavior in nursing home residents: a clinical experience [abstract]. Proceedings of the American Psychiatric Association (APA) 148th Annual Meeting: new research program and abstracts. Miami; 1995 May 20–25; 126

  82. Brecher M. Risperidone in the treatment of psychosis in elderly patients [abstract]. Eighth congress of the International Psychogeriatric Association: Jerusalem: 1997 Aug 17–22: 83

  83. Meco G, Alessandria A, Bonifati V, et al. Risperidone for hallucinations in levodopa-treated Parkinson’s disease patients. Lancet 1994; 343: 1370–1

    Article  PubMed  CAS  Google Scholar 

  84. Ford B, Lynch T, Greene P. Risperidone in Parkinson’s disease [letter; comment]. Lancet 1994; 344: 681

    Article  PubMed  CAS  Google Scholar 

  85. McKeith IG, Ballard CG, Harrison RWS. Neuroleptic sensitivity to risperidone in Lewy body dementia [letter; comment]. Lancet 1995; 346: 699

    Article  PubMed  CAS  Google Scholar 

  86. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson’s disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995; 56: 556–9

    PubMed  CAS  Google Scholar 

  87. Berman I, Merson A, Allan E, et al. Effect of risperidone on cognitive performance in elderly schizophrenic patients: a doubleblind comparison study with haloperidol. Psychopharmacol Bull 1995; 31: 552

    Google Scholar 

  88. Huang ML, Peer AV, Woestenborghs R, et al. Pharmacokinetics and drug disposition: pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993; 54: 257–68

    Article  PubMed  CAS  Google Scholar 

  89. Ereshefsky L, Lacombe S. Pharmacological profile of risperidone. Can J Psychiatry 1993; 38Suppl. 3: S80–8

    PubMed  Google Scholar 

  90. Heykants J, Huang ML, Mannens G, et al. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 1994; 55: 13–7

    PubMed  Google Scholar 

  91. Hoffman DW, Winer MST, Bartels S, et al. Therapeutic dose: serum level relationships of risperidone and active metabolite in a geriatric population. Psychopharmacol Bull 1995; 37(3): 525

    Google Scholar 

  92. Snoeck E, Peer AV, Sack M, et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology 1995; 122: 223–9

    Article  PubMed  CAS  Google Scholar 

  93. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825–35

    PubMed  CAS  Google Scholar 

  94. Leysen JE, Janssen PMF, Schotte A, et al. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology Berl 1993; 112(1 Suppl.): S40–54

    Article  PubMed  CAS  Google Scholar 

  95. Sweet RA, Pollock BG, Mulsant BH, et al. Atypical neuroleptics: pharmacologic considerations. Eur Neuropsychopharmacol 1996; 6: 27–8

    Article  Google Scholar 

  96. Satterlee WG, Reams S, Burns PR, et al. A clinical update on olanzapine treatment in schizophrenia and in elderly Alzheimer’s disease patients. Psychopharmacol Bull 1995; 35(3): 534

    Google Scholar 

  97. Beasley CMJ. Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry Monograph 1997; 15: 16–8

    Google Scholar 

  98. Wolters EC, Jansen ENH, Tuynman-Qua HG, et al. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson’s disease. Neurology 1996; 47: 1082–7

    Article  Google Scholar 

  99. Ring BJ, Binkley SN, Vandenbranden M, et al. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol 1996; 41: 181–6

    Article  PubMed  CAS  Google Scholar 

  100. Sonne J, Loft S, Dossing M, et al. Single dose pharmacokinetics and pharmacodynamics of oral oxazepam in very elderly institutionalized subjects. Br J Clin Pharmacol 1991; 31: 719–22

    Article  PubMed  CAS  Google Scholar 

  101. Fisman M, Inaba T, Kalow W, et al. Oxazepam as a probe of hepatic metabolism in patients with Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12: 255–61

    Article  PubMed  CAS  Google Scholar 

  102. Bymaster FP. In vitro and in vivo biochemistry of olanzapine. J Clin Psychiatry Monograph 1997; 15: 10–2

    Google Scholar 

  103. van Kammen DP, McEvoy JP, Targum SD, et al. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 1996; 124: 168–75

    Article  PubMed  Google Scholar 

  104. Targum SD, Arvanitis LA. Quetiapine: efficacy, safety, and tolerability in elderly subjects with psychotic disorders. Psychopharmacol Bull 1997; 33(3): 595

    Google Scholar 

  105. Stip E, Lussier I, Babai M, et al. Seroquel and cognitive improvement in patients with schizophrenia. Biol Psychiatry 1996; 40: 430–7

    Article  Google Scholar 

  106. Thyrum PT, Jaskiw G, Fuller M, et al. Multiple-dose pharmacokinetics of ICI 204,636 in elderly patients with selected psychotic disorders [abstract]. Psychopharmacol Bull 1996; 32: 524

    Google Scholar 

  107. Wong JYW, Ewing BJ, Thyrum PT, et al. The effect of phenytoin and cimetidine on the pharmacokinetics of quetiapine [abstract]. Proceedings of the American Psychiatric Association (APA) 150th Annual Meeting; new research program and abstracts. San Diego (CA); 1997 May 17–22; 135

  108. Schotte A, Luyten WHML, Van Gompel P, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996; 124: 57–73

    Article  PubMed  CAS  Google Scholar 

  109. Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995; 275: 101–13

    PubMed  CAS  Google Scholar 

  110. Wilner KD, Anziano RJ, Johnson AC, et al. Anxiolytic effects of ziprasidone compared with diazepam and placebo prior to dental surgery [abstract]. Eur Neuropsychopharmacol 1996; 6Suppl. 3: 117

    Article  Google Scholar 

  111. Meyers BS, Greenberg R. Late-life delusional depression. J Affective Disord 1986; 11: 133–7

    Article  CAS  Google Scholar 

  112. Zubenko GS, Mulsant BH, Rifai AH, et al. Impact of acute psychiatric inpatient treatment on major depression in late life and prediction of response. Am J Psychiatry 1994; 151: 987–94

    PubMed  CAS  Google Scholar 

  113. Wilner KD, Hansen RA, Johnson AC, et al. Single and multiple dose pharmacokinetics of ziprasidone in healthy males [abstract]. Eur Neuropsychopharmacol 1996; 6Suppl. 3: 38

    Google Scholar 

  114. Brook S, Swift R, Harrigan EP, et al. The tolerability and efficacy of intramuscular ziprasidone. Psychopharmacol Bull 1997; 33(3): 498

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Geriatric Psychopharmacology Program, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

    Robert A. Sweet & Bruce G. Pollock

Authors
  1. Robert A. Sweet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bruce G. Pollock
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sweet, R.A., Pollock, B.G. New Atypical Antipsychotics. Drugs & Aging 12, 115–127 (1998). https://doi.org/10.2165/00002512-199812020-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199812020-00004

Keywords

Search

Navigation